Tianhong CNI BIOMEDICINE ETF(159859) rises 2.05%, with a scale increase of 32.8216 million yuan over the past week

NewTimeSpace (newtimespace.com) News, as of 13:17 on May 29, 2026, Tianhong Biopharmaceutical ETF (159859) rose 2.05%, with the latest price at 0.35 yuan. (The stocks listed above are only index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Tianhong Biopharmaceutical ETF recorded an intraday turnover rate of 2.36% and a trading volume of 96.4863 million yuan. Over a longer time frame, as of May 28, the ETF's average daily trading volume over the past month reached 136 million yuan, ranking first among comparable funds.

In terms of scale, Tianhong Biopharmaceutical ETF saw a significant increase of 32.8216 million yuan in scale over the past week, with the new scale increase ranking 1/3 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of Tianhong Biopharmaceutical ETF reached 11.828 billion units, hitting a one-year high and ranking 1/3 among comparable funds. (Data source: Wind)

In terms of net capital inflow, Tianhong Biopharmaceutical ETF saw consecutive net inflows for five days, with the highest single-day net inflow reaching 83.6958 million yuan. It attracted a total of 285 million yuan, with an average daily net inflow of 57.0253 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. Tianhong Biopharmaceutical ETF has seen net purchases by leveraged funds for five consecutive days, with the highest single-day net purchase reaching 21.2925 million yuan. The latest margin financing balance stood at 217 million yuan. (Data source: Wind)

From the perspective of return capability, as of May 28, 2026, since its inception, Tianhong Biopharmaceutical ETF achieved a highest single-month return of 27.87%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 31.58%, and an average return of 5.35% in up months. As of May 28, 2026, the ETF's annualized excess return over its benchmark since inception was 1.87%.

In terms of drawdown, as of May 28, 2026, Tianhong Biopharmaceutical ETF recorded a drawdown of 0.08% relative to its benchmark since the beginning of the year, the smallest drawdown among comparable funds.

In terms of fees, Tianhong Biopharmaceutical ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of May 28, 2026, the tracking error of Tianhong Biopharmaceutical ETF since the beginning of the year was 0.015%, achieving the highest tracking accuracy among comparable funds.

It is worth noting that the valuation of the Guosen Biopharmaceutical Index, which the fund tracks, is at a historical low. The latest price-to-book (PB) ratio is 2.88x, which is lower than over 94.57% of the time in the past year, highlighting attractive valuation.

Tianhong Biopharmaceutical ETF closely tracks the Guosen Biopharmaceutical Index. The Guosen Biopharmaceutical Index takes listed companies related to the biopharmaceutical industry on the Shanghai, Shenzhen, and Beijing stock exchanges as the sample space. Based on a comprehensive ranking of market capitalization and liquidity, it selects the top 30 securities as index constituents. It reflects the overall operation of the biopharmaceutical industry and provides market participants with index-based investment targets for the sub-industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.